Eupraxia Pharmaceuticals Inc. (EPRX) Dividend History

Company News

• Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

  Eupraxia Pharmaceuticals announced the results of its Annual General and Special Meeting of Shareholders, where all six proposed directors were elected, and other business items were approved by shareholders.

  GlobeNewswire Inc.
• “Bear-Pit Session” Highlights Peterson Capital’s Canada Growth Conference in Montreal

  Nine public company CEOs participated in a 'Bear-Pit' session at the Canada Growth Conference hosted by Peterson Capital in Montreal. Eupraxia Pharmaceuticals was voted the top growth story, but all companies received investor support.

  GlobeNewswire Inc.
• Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025

  Eupraxia Pharmaceuticals is hosting a virtual event to discuss additional data from its Phase 1b/2a RESOLVE study evaluating EP-104GI for the treatment of eosinophilic esophagitis (EoE). The event will feature a key opinion leader who will discuss the unmet need and current treatment landscape for EoE, and how the data from the RESOLVE study demonstrates the potential for EP-104GI to become a new standard of care.

  GlobeNewswire Inc.
• Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

  Eupraxia Pharmaceuticals announced positive nine-month data from its ongoing Phase 1b/2a RESOLVE trial, which showed sustained or improved treatment outcomes in patients with eosinophilic esophagitis (EoE) after a single treatment with 48mg dose of EP-104GI. The company believes these results provide further evidence of the precision and durability of its DiffuSphere™ technology.

  GlobeNewswire Inc.
• Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May

  Eupraxia Pharmaceuticals, a clinical-stage biotechnology company, announced that its management and scientific teams will present at various investor and scientific conferences in April and May 2025, showcasing data from their ongoing studies on osteoarthritis and eosinophilic esophagitis.

  GlobeNewswire Inc.